TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02251782

Intervention type: DEVICE
Intervention: Epi proColon Test
Description: Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.

Intervention type: DEVICE
Intervention: Fecal Immunochemical Test (FIT)
Description: Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
Study: NCT00942422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein analysis
Description: Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
Study: NCT04360889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)
Description: Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)

Intervention type: OTHER
Group type: OTHER
Intervention: Elastic compression
Description: patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
Study: NCT00784160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Description: Lactic Acid
Study: NCT01696708

Intervention type: OTHER
Group type: OTHER
Intervention: 31-Phosphorus RMN Spectroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: 31-Phosphorus RMN Spectroscopy
Study: NCT01614951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion of the lungs
Description: Pulmonary perfusion with oxygenated blood during ECC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTK Custodiol
Description: Pulmoplegia before ECC.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard ECC
Description: ECC after standard procedure
Study: NCT02509195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
Study: NCT01499446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X (fluticasone furoate) 100mcg Evening
Description: GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW685698X (fluticasone furoate) 100mcg Evening
Description: GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X (fluticasone furoate) 250mcg Evening
Description: GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW685698X (fluticasone furoate) 250mcg Evening
Description: GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled twice daily (morning and evening) for 28 days
Study: NCT03903211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study: NCT03958695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)
Description: A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator mid-urethral tape, Urosling (Lintex, LLC)
Description: A transobturator tension-free mid-urethral sling
Study: NCT02269709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI Ultrasound
Description: This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
Study: NCT02967965

Intervention type: OTHER
Intervention: Imagery
Description: MRI at year 3
Study: NCT03903211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study: NCT00890604

Intervention type: OTHER
Group type: OTHER
Intervention: Stepwise normothermia protocol
Description: Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
Study: NCT01295736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 20 mg TID per os during 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills TID per os during 90 days
Study: NCT03765151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic retention
Description: All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: orthodontic retention
Description: All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
Study: NCT00111540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
Study: NCT03306641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens
Description: Daily disposable contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens
Description: Daily disposable contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A
Description: Focus Dailies All Day Comfort contact lens (nelfilcon A)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A
Description: Focus Dailies All Day Comfort contact lens (nelfilcon A)
Study: NCT00499408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy
Description: Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
Study: NCT00539929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.005%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.01%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.03%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.03%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00494715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril
Description: Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/Valsartan
Description: Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study: NCT01902459

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EVARREST™ Fibrin Sealant Patch
Description: EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
Study: NCT03216759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia
Description: Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
Study: NCT00084981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00694213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-IPM1
Description: IM, 0.5 mg/mL, 2 injections, 0 and 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-IPM1
Description: IM, 1 mg/mL, 2 injections, 0 and 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-IPT1
Description: IM, 1 mg/mL, 2 injections, 0 and 21 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: IM, 1 mL, 2 injections, 0 and 21 days
Study: NCT01830582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced MR Imaging
Study: NCT02746991

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAI Insert
Description: Fluocinolone Acetonide
Study: NCT00245726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycle
Description: Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ES therapy
Description: Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive (Motor Assist) Cycle
Description: Subjects will use a cycle that moves the legs for 1 hour/3x per week
Study: NCT00890604

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: Acetominophen
Description: It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
Study: NCT03709212

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
Study: NCT02544256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
Study: NCT03709212

Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
Study: NCT02892929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescriptive Consultation
Description: Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
Study: NCT03378752

Intervention type: PROCEDURE
Intervention: HFJV
Description: On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
Study: NCT02971098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced activity
Description: Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
Study: NCT04585880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Collaborative Care Clinic
Description: The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
Study: NCT03449446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: 18 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: 18 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: 18 mg tablet administered orally once daily without regard to food
Study: NCT00795912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
Study: NCT03449446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: 20 mg tablet administered orally once daily without regard to food
Study: NCT02038660

Intervention type: DEVICE
Intervention: Balloon angioplasty